Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Interventions: Polymotion Hip Resurfacing (PHR) System; Device
Lead sponsor: JointMedica Inc.; Other
Eligibility: 21 Years to 65 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Chlamydia, Gonorrhea
Interventions: Not listed
Lead sponsor: Siemens Healthcare Diagnostics Inc; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Rochester, Minnesota + 1 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Trifluridine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 50
States / cities: Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more

Conditions: Dry Eye Disease
Interventions: SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%, SY-201 Ophthalmic Solution Vehicle; Drug
Lead sponsor: Seinda Pharmaceutical Guangzhou Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acromegaly
Interventions: MAR002, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Solid Tumors
Interventions: I-131-CLR1404; Drug
Lead sponsor: Cellectar, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more

Conditions: Dry Eye
Interventions: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Myelodysplastic Syndromes
Interventions: Deferasirox, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more

Conditions: Hepatobiliary Cancers
Interventions: Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more

Conditions: Multiple Sclerosis
Interventions: Methylprednisolone, ACTH, IV placebo, IM placebo; Drug · Other
Lead sponsor: Neurologique Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ponte Vedra, Florida

Conditions: Alveolar Bone Loss
Interventions: INFUSE® Bone Graft; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more

Conditions: Alzheimer's Disease
Interventions: CNP520, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Glendale, California • Long Beach, California • Miami, Florida + 1 more

Conditions: Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma, Age Related Macular Degeneration
Interventions: Blue-light filtering intraocular lens, Conventional intraocular lens; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 10,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions: Cobomarsen; Drug
Lead sponsor: miRagen Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: End Stage Renal Disease on Dialysis, Adult
Interventions: Intravenous fosmanogepix; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more

Conditions: Parkinson's Disease
Interventions: 2 mg perampanel, 4 mg perampanel, placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 99
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more

Conditions: Post-Ischemic Stroke
Interventions: Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 70
States / cities: Gilbert, Arizona • Berkeley, California • Long Beach, California + 61 more

Conditions: Hernia, Inguinal
Interventions: OTTAVA Robotic System; Device
Lead sponsor: Auris Health, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Tampa, Florida • Carmel, Indiana • Durham, North Carolina + 1 more

Conditions: Dravet Syndrome
Interventions: EPX-100 (Clemizole Hydrochloride), Placebos; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Huntington's Disease
Interventions: No Study Drug was Administered in this Study; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more

Search by objective public record fields.

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Study of MAR002 in Healthy Men

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Observational Study Protocol: LIVER-R

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

Localized Alveolar Ridge Augmentation With Dental Implant

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Association Between Light Spectrum and Survival After Cataract Surgery

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

Safety and Performance of the OTTAVA System in Participants Undergoing Inguinal Hernia Repair

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus